BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

...I testing of NT-113 in glioblastoma and EGFR-positive solid tumors that metastasize to the brain. NewGen Therapeutics Inc....
BioCentury | Apr 29, 2013
Clinical News

NewGen, Kanion preclinical data

...EGFR2 ( HER2 ; ErbB2 ; neu) and EGFR4 ( HER4 ; ErbB4) in 2014. NewGen...
...EGFR. NewGen has exclusive, ex-Chinese rights to NT-113 from Kanion (see BioCentury, Jan. 2, 2012). NewGen Therapeutics Inc....
BioCentury | Jan 16, 2012
Emerging Company Profile

NewGen: Compositions matter

...former senior executives of ChemGenex Pharmaceuticals Ltd. have reunited to build another cancer company - NewGen Therapeutics Inc....
...had been used in China for many years to treat CML, according to Harry Pedersen, NewGen's...
...said Dennis Brown, who was a co-founder of ChemGenex and is co-founder and CSO of NewGen...
BioCentury | Jan 2, 2012
Company News

NewGen, Kanion deal

...on the compounds. NewGen Therapeutics Inc. , Menlo Park, Calif. Kanion Pharmaceutical Co. Ltd. (Shanghai:600557), Lianyungang, China NewGen...
...testing for solid tumors, while NT-113 and NT-125 are also being evaluated for hematological malignancies. NewGen...
BioCentury | May 23, 2011
Company News

NewGene Ltd. sales and marketing update

NewGene launched its hereditary breast cancer full gene sequencing test in France and Germany. The test identifies all mutations in breast cancer 1 early onset (BRCA1) and BRCA2 . NewGene Ltd. , Newcastle upon Tyne, U.K. Business:...
BioCentury | Jul 22, 2002
Company News

Genetronics management update

...TSE:GEB), San Diego, Calif. Business: Drug delivery Hired: Peter Kies as CFO, formerly CFO at Newgen...
Items per page:
1 - 6 of 6
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

...I testing of NT-113 in glioblastoma and EGFR-positive solid tumors that metastasize to the brain. NewGen Therapeutics Inc....
BioCentury | Apr 29, 2013
Clinical News

NewGen, Kanion preclinical data

...EGFR2 ( HER2 ; ErbB2 ; neu) and EGFR4 ( HER4 ; ErbB4) in 2014. NewGen...
...EGFR. NewGen has exclusive, ex-Chinese rights to NT-113 from Kanion (see BioCentury, Jan. 2, 2012). NewGen Therapeutics Inc....
BioCentury | Jan 16, 2012
Emerging Company Profile

NewGen: Compositions matter

...former senior executives of ChemGenex Pharmaceuticals Ltd. have reunited to build another cancer company - NewGen Therapeutics Inc....
...had been used in China for many years to treat CML, according to Harry Pedersen, NewGen's...
...said Dennis Brown, who was a co-founder of ChemGenex and is co-founder and CSO of NewGen...
BioCentury | Jan 2, 2012
Company News

NewGen, Kanion deal

...on the compounds. NewGen Therapeutics Inc. , Menlo Park, Calif. Kanion Pharmaceutical Co. Ltd. (Shanghai:600557), Lianyungang, China NewGen...
...testing for solid tumors, while NT-113 and NT-125 are also being evaluated for hematological malignancies. NewGen...
BioCentury | May 23, 2011
Company News

NewGene Ltd. sales and marketing update

NewGene launched its hereditary breast cancer full gene sequencing test in France and Germany. The test identifies all mutations in breast cancer 1 early onset (BRCA1) and BRCA2 . NewGene Ltd. , Newcastle upon Tyne, U.K. Business:...
BioCentury | Jul 22, 2002
Company News

Genetronics management update

...TSE:GEB), San Diego, Calif. Business: Drug delivery Hired: Peter Kies as CFO, formerly CFO at Newgen...
Items per page:
1 - 6 of 6